ClinicalTrials.gg
Active, not recruitingNCT04221477REGENCYUpdated Oct 19, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

A Phase 3 interventional study of Obinutuzumab and MMF in Lupus Nephritis, sponsored by Hoffmann-La Roche. Active, not recruiting at 74 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.

Enrollment
3rd of 11
271 · median 52
Started
2020
the only one that year
Phase 3
7 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 8th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Nephritis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN as evidenced by renal performed within 6 months. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease
  • Urine protein to creatinine ratio greater than or equal to (>/=) 1 on a 24-hour collection
  • Other inclusion criteria may apply

Key Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Severe renal impairment or the need for dialysis or renal transplantation
  • Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
  • Known active infection of any kind or recent major episode of infection
  • Intolerance or to study therapies
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    Obinutuzumab

    Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80. After study unblinding, participants may be eligible for further open-label obinutuzumab treatment.

    Drug: Obinutuzumab · Drug: MMF · Drug: Prednisone · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine

  • Placebo comparator
    Placebo

    Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80. After study unblinding, participants may be eligible for further open-label obinutuzumab treatment.

    Drug: Obinutuzumab · Drug: MMF · Drug: Prednisone · Drug: Placebo · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine

Interventions

  • Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.

    Also known as: Gazyva, GA101, RO5072759

  • DrugMMF

    MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.

  • Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.

  • DrugPlacebo

    Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.

  • Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.

  • Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

  • Diphenhydramine 50 mg will be administered as premedication prior to infusions.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Renal Response (CRR)

    CRR was defined as an achievement of all the following criteria: urinary protein-to-creatinine ratio (UPCR) \<0.5 gram/gram (g/g); estimated glomerular filtration rate (eGFR) \>=85% of baseline, as calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Obinutuzumab and placebo were compared using Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using fully conditional specification (FCS) predicted mean matching method. Percentage have been rounded off.

    Time frame: At Week 76

Secondary outcomes

  1. Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76

    CRR with successful prednisone was defined as the achievement of CRR at Week 76 with no receipt of prednisone \>7.5 milligrams per day (mg/day) (or equivalent) from Week 64 through Week 76. CRR was defined as achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

    Time frame: At Week 76

  2. Percentage of Participants Who Achieve a Proteinuric Response

    Proteinuric response was defined as an achievement of all the following criteria: UPCR \<0.8 g/g and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

    Time frame: At Week 76

  3. Mean Change in eGFR

    Change in eGFR from baseline to Week 76 was analyzed using Analysis of Covariance (ANCOVA) model with covariates baseline eGFR and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. mL/min/1.73 m\^2 = milliliters per minute per 1.73 square meters. Adjusted mean has been reported.

    Time frame: At Week 76

  4. Percentage of Participants Who Experience Death or Renal-related Events

    Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value \<60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.

    Time frame: From Day 1 to Week 76

  5. Percentage of Participants Who Achieve an Overall Renal Response (ORR)

    ORR was defined as achievement of either CRR or PRR. CRR was defined as achievement of all of the criteria: UPCR \<0.5 g/g; eGFR ≥85% of baseline, as calculated using the CKD-EPI equation. PRR was defined as achievement of all of the following criteria: ≥50% reduction in UPCR from baseline; UPCR \<1 g/g (or \<3 g/g if the baseline UPCR was ≥3 g/g); eGFR ≥85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

    Time frame: At Week 50

  6. Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale

    The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-F score of 0 (worse score) to 52 (better score). Higher scores indicate less fatigue. Change in FACIT-F score from baseline at Week 76 was analyzed using ANCOVA model with covariates baseline FACIT-F score and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing FACIT-F score after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

    Time frame: At Week 76

  7. Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer

    Anti-dsDNA are types of autoantibodies produced by the immune system and are indicators of lupus. Anti-dsDNA data was log-transformed before analysis. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with upper limit of quantification (ULOQ, 890 international units/milliliter \[IU/mL\]). Adjusted mean has been reported.

    Time frame: At Week 50

  8. Change in Complement C3

    C3 is a marker of inflammation. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with lower limit of quantification (LLOQ)/2 under composite strategy. LLOQ at the central lab was set for C3 at 0.100 grams/liters (g/L). Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

    Time frame: At Week 50

  9. Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    The SLEDAI-2K is a 24-item instrument that evaluates clinical symptoms and laboratory markers across nine organ systems and was used to capture changes in lupus-related disease activity. SLE manifestations are assessed by the clinician if present within the last 30 days and added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Higher scores indicate increased disease activity. The analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 105, the highest possible score. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

    Time frame: At Week 76

  10. Time to Onset of CRR

    CRR was defined as an achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.

    Time frame: From baseline (Day 1) up to 80.3 weeks

  11. Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria

    CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR \<0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by \> 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.

    Time frame: At Week 76

  12. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: Up to Week 76

  13. Number of Participants With Adverse Events of Special Interest (AESIs)

    An AE was any untoward medical occurrence in participant administered a pharmaceutical product \& which does not necessarily have to have a causal relationship with treatment. It can therefore be any unfavorable \& unintended sign (including abnormal laboratory values/ abnormal clinical test results), symptoms, or disease temporally associated with use of pharmaceutical product, whether or not considered related to product. AESIs included potential drug-induced liver injury that include an elevated alanine transaminase (ALT) \& aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice defined by Hy's law; suspected transmission of an infectious agent by study drug; infusion-related reactions (IRRs); grade 3/higher infections; any hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML); drug-related neutropenia; drug-related thrombocytopenia; gastrointestinal perforations and worsening of pre-existing cardiac conditions

    Time frame: Up to Week 76

  14. Number of Participants With Anti-Drug Antibodies (ADAs) Positive Post-Treatment

    Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).

    Time frame: Up to approximately 11 years

  15. Total Peripheral B-Cell (CD19) Count

    Time frame: Up to approximately 11 years

  16. Concentration of Obinutuzumab in Serum

    Time frame: Up to approximately 11 years

07

Results

Posted Nov 6, 2025

Participant flow

A total of 271 participants with International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis (LN) treated with standard-of-care (SOC) therapy took part in the study across 72 sites in 15 countries. This study consists of blinded treatment with obinutuzumab or placebo, followed by open-label treatment (OLT) with obinutuzumab.

Participant flow — Overall Study
MilestoneObinutuzumabPlacebo
Started135136
Safety population136132
Completed week 76 assessment122120
Completed00
Not completed135136
Withdrew: Adverse event11
Withdrew: Death54
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up12
Withdrew: Non-compliance with study drug10
Withdrew: Reason not specified05
Withdrew: Physician decision06
Withdrew: Withdrawal by subject1014
Withdrew: Ongoing in the study116102

Outcome measures

PrimaryPercentage of Participants With Complete Renal Response (CRR)

CRR was defined as an achievement of all the following criteria: urinary protein-to-creatinine ratio (UPCR) \<0.5 gram/gram (g/g); estimated glomerular filtration rate (eGFR) \>=85% of baseline, as calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Obinutuzumab and placebo were compared using Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using fully conditional specification (FCS) predicted mean matching method. Percentage have been rounded off.

Time frame:
At Week 76
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Renal Response (CRR)
percentage of participantsObinutuzumabPlacebo
Percentage of Participants With Complete Renal Response (CRR)46.4 (37.95 to 54.86)33.1 (25.18 to 41.00)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0232 (Test 1 of 7 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Adjusted difference: 13.40 · 95% CI 1.95 to 24.84
SecondaryPercentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76

CRR with successful prednisone was defined as the achievement of CRR at Week 76 with no receipt of prednisone \>7.5 milligrams per day (mg/day) (or equivalent) from Week 64 through Week 76. CRR was defined as achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

Time frame:
At Week 76
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 7642.7 (34.32 to 51.09)30.9 (23.12 to 38.65)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0421 (Test 2 of 7 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Adjusted difference: 11.88 · 95% CI 0.57 to 23.18
SecondaryPercentage of Participants Who Achieve a Proteinuric Response

Proteinuric response was defined as an achievement of all the following criteria: UPCR \<0.8 g/g and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

Time frame:
At Week 76
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Proteinuric Response
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieve a Proteinuric Response55.5 (47.09 to 63.95)41.9 (33.62 to 50.20)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0227 (Test 3 of 7 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.04 with fallback method.) · Adjusted difference: 13.68 · 95% CI 2.01 to 25.36
SecondaryMean Change in eGFR

Change in eGFR from baseline to Week 76 was analyzed using Analysis of Covariance (ANCOVA) model with covariates baseline eGFR and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. mL/min/1.73 m\^2 = milliliters per minute per 1.73 square meters. Adjusted mean has been reported.

Time frame:
At Week 76
Reported as:
Mean · mL/min/1.73 m^2
Mean Change in eGFR
mL/min/1.73 m^2ObinutuzumabPlacebo
Mean Change in eGFR2.31 ± 2.713-1.54 ± 2.706
Statistical analysis
  • Obinutuzumab vs Placebo · ANCOVA · p = 0.1842 (Test 4 of 7 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Difference in adjusted means: 3.84 · 95% CI -1.83 to 9.51
SecondaryPercentage of Participants Who Experience Death or Renal-related Events

Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value \<60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.

Time frame:
From Day 1 to Week 76
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience Death or Renal-related Events
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Experience Death or Renal-related Events18.9 (12.11 to 25.61)35.6 (27.50 to 43.78)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0026 (Ranked 5 of 7 in the fixed sequence for type I error control. P-value is nominal as the hierarchical testing stops at the first non-significant endpoint.) · Adjusted difference: -16.83 · 95% CI -27.42 to -6.23
SecondaryPercentage of Participants Who Achieve an Overall Renal Response (ORR)

ORR was defined as achievement of either CRR or PRR. CRR was defined as achievement of all of the criteria: UPCR \<0.5 g/g; eGFR ≥85% of baseline, as calculated using the CKD-EPI equation. PRR was defined as achievement of all of the following criteria: ≥50% reduction in UPCR from baseline; UPCR \<1 g/g (or \<3 g/g if the baseline UPCR was ≥3 g/g); eGFR ≥85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.

Time frame:
At Week 50
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an Overall Renal Response (ORR)
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieve an Overall Renal Response (ORR)59.1 (50.80 to 67.43)50.7 (42.16 to 59.22)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.1670 (Ranked 6 of 7 in the fixed sequence for type I error control.) · Adjusted difference: 8.36 · 95% CI -3.41 to 20.12
SecondaryChange From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale

The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-F score of 0 (worse score) to 52 (better score). Higher scores indicate less fatigue. Change in FACIT-F score from baseline at Week 76 was analyzed using ANCOVA model with covariates baseline FACIT-F score and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing FACIT-F score after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

Time frame:
At Week 76
Reported as:
Mean · score on a scale
Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
score on a scaleObinutuzumabPlacebo
Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale1.76 ± 1.2233.11 ± 1.212
Statistical analysis
  • Obinutuzumab vs Placebo · ANCOVA · p = 0.2991 (Ranked 7 of 7 in the fixed sequence for type I error control.) · Difference in adjusted means: -1.35 · 95% CI -3.89 to 1.20
SecondaryChange in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer

Anti-dsDNA are types of autoantibodies produced by the immune system and are indicators of lupus. Anti-dsDNA data was log-transformed before analysis. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with upper limit of quantification (ULOQ, 890 international units/milliliter \[IU/mL\]). Adjusted mean has been reported.

Time frame:
At Week 50
Reported as:
Mean · Log (IU/mL)
Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer
Log (IU/mL)ObinutuzumabPlacebo
Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer-0.38 ± 0.100-0.01 ± 0.099
Statistical analysis
  • Obinutuzumab vs Placebo · ANCOVA · p = 0.0006 (Not type I error controlled.) · Difference in adjusted means: -0.36 · 95% CI -0.57 to -0.16
SecondaryChange in Complement C3

C3 is a marker of inflammation. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with lower limit of quantification (LLOQ)/2 under composite strategy. LLOQ at the central lab was set for C3 at 0.100 grams/liters (g/L). Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

Time frame:
At Week 50
Reported as:
Mean · g/L
Change in Complement C3
g/LObinutuzumabPlacebo
Change in Complement C30.20 ± 0.0300.06 ± 0.030
Statistical analysis
  • Obinutuzumab vs Placebo · ANCOVA · p = <0.0001 (Not type I error controlled) · Difference in adjusted means: 0.14 · 95% CI 0.08 to 0.20
SecondaryChange in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

The SLEDAI-2K is a 24-item instrument that evaluates clinical symptoms and laboratory markers across nine organ systems and was used to capture changes in lupus-related disease activity. SLE manifestations are assessed by the clinician if present within the last 30 days and added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Higher scores indicate increased disease activity. The analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 105, the highest possible score. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.

Time frame:
At Week 76
Reported as:
Mean · score on a scale
Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
score on a scaleObinutuzumabPlacebo
Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)-5.63 ± 1.456-5.51 ± 1.432
Statistical analysis
  • Obinutuzumab vs Placebo · ANCOVA · p = 0.9384 (Not type I error controlled.) · Difference in adjusted means: -0.12 · 95% CI -3.11 to 2.87
SecondaryTime to Onset of CRR

CRR was defined as an achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.

Time frame:
From baseline (Day 1) up to 80.3 weeks
Reported as:
Median · weeks
Time to Onset of CRR
weeksObinutuzumabPlacebo
Time to Onset of CRR76.4 (76.1 to 77.4)80.3 (76.3 to NA)
Statistical analysis
  • Obinutuzumab vs Placebo · Log Rank · p = 0.1324 (Not type I error controlled.) · Hazard ratio (hr): 1.31 · 95% CI 0.91 to 1.89
SecondaryPercentage of Participants Who Achieve CRR With Serum Creatinine Criteria

CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR \<0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by \> 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.

Time frame:
At Week 76
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria46.4 (37.90 to 54.85)33.1 (25.18 to 41.00)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0237 (Not type I error controlled.) · Adjusted difference: 13.37 · 95% CI 1.91 to 24.82
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

Time frame:
Up to Week 76
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsObinutuzumabPlacebo
Number of Participants With Adverse Events (AEs)126117
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs)

An AE was any untoward medical occurrence in participant administered a pharmaceutical product \& which does not necessarily have to have a causal relationship with treatment. It can therefore be any unfavorable \& unintended sign (including abnormal laboratory values/ abnormal clinical test results), symptoms, or disease temporally associated with use of pharmaceutical product, whether or not considered related to product. AESIs included potential drug-induced liver injury that include an elevated alanine transaminase (ALT) \& aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice defined by Hy's law; suspected transmission of an infectious agent by study drug; infusion-related reactions (IRRs); grade 3/higher infections; any hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML); drug-related neutropenia; drug-related thrombocytopenia; gastrointestinal perforations and worsening of pre-existing cardiac conditions

Time frame:
Up to Week 76
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsObinutuzumabPlacebo
IRRs2115
Grade 3-5 infection219
Any Hepatitis B reactivation and PML00
Drug related Neutropenia175
Drug related Thrombocytopenia10
Gastrointestinal Perforations00
Worsening of pre-existing Cardiac Conditions02
Hy's Law00
Suspected Transmission of an Infectious Agent by the Study Drug00
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) Positive Post-Treatment

Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).

Time frame:
Up to approximately 11 years

Results for this outcome have not been posted.

SecondaryTotal Peripheral B-Cell (CD19) Count
Time frame:
Up to approximately 11 years

Results for this outcome have not been posted.

SecondaryConcentration of Obinutuzumab in Serum
Time frame:
Up to approximately 11 years

Results for this outcome have not been posted.

Adverse events

Collected over Up to Week 76 Data collected up to the primary completion date (Up to Week 76) is reported. Data collection post Week 76 is still ongoing. Final data will be reported 1 year after the study completion date. As pre-specified in the SAP, safety data were to be provided for obinutuzumab (combined treatment groups) and placebo groups. AE data were collected for all Obinutuzumab participants together, without regard to or information of the specific Obinutuzumab group participants they were part of.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab5/136 (3.7%)44/136 (32.4%)107/136 (78.7%)
Placebo4/132 (3%)24/132 (18.2%)94/132 (71.2%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventObinutuzumabPlacebo
COVID-19 pneumoniaInfections and infestations7/1360/132
NeutropeniaBlood and lymphatic system disorders4/1360/132
COVID-19Infections and infestations4/1361/132
PneumoniaInfections and infestations4/1363/132
Urinary tract infectionInfections and infestations4/1362/132
GastroenteritisInfections and infestations3/1362/132
Acute kidney injuryRenal and urinary disorders3/1362/132
CholecystitisHepatobiliary disorders0/1362/132
Nephrotic syndromeRenal and urinary disorders1/1362/132
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1362/132
Most frequent other events
Showing 10 of 24
Most frequent other events
EventObinutuzumabPlacebo
COVID-19Infections and infestations35/13630/132
DiarrhoeaGastrointestinal disorders28/13621/132
Urinary tract infectionInfections and infestations19/13615/132
Infusion related reactionInjury, poisoning and procedural complications19/13614/132
Upper respiratory tract infectionInfections and infestations16/13613/132
BronchitisInfections and infestations13/13611/132
NeutropeniaBlood and lymphatic system disorders12/1364/132
HeadacheNervous system disorders12/1368/132
NauseaGastrointestinal disorders8/13611/132
VomitingGastrointestinal disorders10/13611/132

Baseline characteristics

Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, demographic and baseline characteristics were to be provided for obinutuzumab (combined treatment groups) and placebo groups.

Age, Continuous
Age, Continuous(years)ObinutuzumabPlaceboTotal
Mean33.0 ± 10.532.7 ± 10.032.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)ObinutuzumabPlaceboTotal
Female114115229
Male212142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObinutuzumabPlaceboTotal
Hispanic or Latino7185156
Not Hispanic or Latino5448102
Unknown or Not Reported10313
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ObinutuzumabPlaceboTotal
American Indian or Alaska Native252651
Asian9716
Native Hawaiian or Other Pacific Islander000
Black or African American202040
White6564129
More than one race11920
Unknown or Not Reported51015
08

Study locations

74 sites
09

References and documents

Publications

  • Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martinez G, Zuta Santillan AE, Alvarez D, Navarro Sandoval C, Lila AM, Tumlin JA, Saxena A, Irazoque Palazuelos F, Raghu H, Yoo B, Hassan I, Martins E, Sehgal H, Kirchner P, Ross Terres J, Omachi TA, Schindler T, Pendergraft WF 3rd, Malvar A; REGENCY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025 Apr 17;392(15):1471-1483. doi: 10.1056/NEJMoa2410965. Epub 2025 Feb 7. PubMed 39927615 ↗
  • Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230. PubMed 37528520 ↗
  • Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. No abstract available. PubMed 33693991 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Aug 2024, 48 months.

Results were first posted in Nov 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 9, 2020
StartActual
Aug 10, 2020
Primary completionActual
Aug 15, 2024
CompletionEst.
Mar 2, 2031
Results first posted
Nov 6, 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04221477
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 9, 2020
Start date
Aug 10, 2020
Primary completion
Aug 15, 2024
Completion
Mar 2, 2031 (estimated)
Results posted
Nov 6, 2025
Last update
Oct 19, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion